Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. METHODS: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-CSF and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. RESULTS: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66±5% vs. 46±5% at 2 years, P=0.01) and overall survival (86±4% vs. 75±5% at 2 years, P=0.02 without adjustment for interim analyses). CONCLUSIONS: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60983-0 · Cited by 2,032
Self-citationMatthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898 · cited 2×
“Hypersensitivity reaction 14 (10) 33 (26) 6 (5) 29 (25) 13 (12) 3 (3)”
Self-citationWeng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“Complete response 38 (34) 40 (35) 78 (35) 61±7 86±5”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Matthay, K. K., Reynolds, C. P., Seeger, R. C., Shimada, H., Adkins, E. S., Haas-Kogan, D., Gerbing, R. B., London, W. B., & Villablanca, J. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.8925 · Cited by 858 · cited 1×
“Pain 50 (37) 30 (24) 23 (19) 33 (29) 15 (14) 4 (4)”
Self-citationAdoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Research works printed but not linked: 10
- Schulz G, 1984, Cancer Res, 44, 5914
- Yu AL, 1997, Proc Am Soc Oncol, 6, 1846
- Barker E, 1991, Cancer Res, 51, 144
- Albertini MR, 1997, Clin Cancer Res, 3, 1277
- Hank JA, 1990, Cancer Res, 50, 5234
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Greenwood M, 1926, Rep Public Health Med Subj (Lond), 33, 1
- Barker E, 1993, Cancer Res, 53, 362
- Dallegri F, 1989, Clin Exp Immunol, 77, 58
- Simon T, 2009, Pediatr Blood Cancer, 53, 708
Cited by
Items 601–700 of 1,000
Dinutuximab for maintenance therapy in pediatric neuroblastoma
McGinty, L., & Kolesar, J. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160228 · Cited by 30
Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research
Sharma, R., Yadav, J., Bhat, S. A., Musayev, A., Myrzagulova, S., Sharma, D., Padha, N., Saini, M., Tuli, H. S., & Singh, T. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04680-w · Cited by 36
“18) Dinutuximab mAb binds to the GD2 and activates the complement system [247] and also mediates ADCC by neutrophils and NK cells [248].”
Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma
Büchel, G., Schulte, J. H., Harrison, L., Batzke, K., Schüller, U., Hansen, W., & Schramm, A. R. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131378 · Cited by 29
Chemical synthesis and immunological evaluation of entirely carbohydrate conjugate Globo H-PS A1
Ghosh, S., Trabbic, K. R., Shi, M., Nishat, S., Eradi, P., Kleski, K. A., & Andreana, P. R. (2020) · Chemical Science · doi:10.1039/d0sc04595k · Cited by 29
CD276 as a novel CAR NK‐92 therapeutic target for neuroblastoma
Grote, S., Chan, K. C.-H., Baden, C., Bösmüller, H. C., Sulyok, M., Frauenfeld, L., Ebinger, M., Handgretinger, R., & Schleicher, S. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.105 · Cited by 30
Neuroblastoma: Essential genetic pathways and current therapeutic options
Salemi, F., Alam, W., Hassani, M. S., Hashemi, S. Z., Jafari, A. A., Mirmoeeni, S., Arbab, M., Mortazavizadeh, S. M. R., & Khan, H. Z. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175030 · Cited by 35
IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
Stip, M. C., Evers, M., Nederend, M., Chan, C., Reiding, K. R., Damen, M. J. A., Heck, A. J. R., Koustoulidou, S., Ramakers, R. M., Krijger, G. C., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006948 · Cited by 29
Kushner, B. H., Modak, S. I., Basu, E. M., Roberts, S. S., Kramer, K., & Cheung, N. V. (2013) · Cancer · doi:10.1002/cncr.28137 · Cited by 30
“In reports on anti-GD2 MoAb treatment, the hallmark features of PRES are rare, with significant hypertension, CNS cortical symptoms, and emesis in 0% to 5% of patients.(9-21,25-36) In our series, 1 patient failed to complete prior treatment with the anti-GD2 ch14.”
BackgroundGlioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness
Woo, S. R., Oh, Y. T., An, J. Y., Kang, B. G., Nam, D., & Joo, K. M. (2015) · Anatomy & Cell Biology · doi:10.5115/acb.2015.48.1.44 · Cited by 33
“Currently, several GD2 targeting antibodies have already been developed and studied by many researchers for molecular targeting therapy, and are in clinical trial for neuroblastoma and metastatic melanoma [36, 37].”
BackgroundAhmed, M., Modak, S. I., & Sequeira, S. M. (2013) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000024 · Cited by 30
Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma
Ehrlich, D. J., Wang, B., Lü, W., Dowling, P. C., & Yuan, R. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0091-3 · Cited by 30
“18 mAb drastically improved survival in high risk NB patients [24].”
BackgroundFeng, Y., Wang, Y., Zhu, Z., Li, W., Sussman, R. T., Randall, M. P., Bosse, K. R., Maris, J. M., & Dimitrov, D. S. (2016) · mAbs · doi:10.1080/19420862.2016.1155014 · Cited by 29
“However, this product causes debilitating pain due to GD2 expression on normal peripheral nerves.(3) Thus, alternative immunotherapeutic strategies to improve outcomes for patients with neuroblastoma are needed.”
BackgroundSelf-citationLi, R. C., Polishchuk, A. L., DuBois, S. G., Hawkins, R. A., Lee, S. W., Bagatell, R., Shusterman, S., Hill‐Kayser, C. E., Al‐Sayegh, H., Diller, L., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.10.047 · Cited by 30
Self-citationBhunia, S., Radha, V., & Chaudhuri, A. (2016) · Nanoscale · doi:10.1039/c6nr07532k · Cited by 29
Anti-tumor effect of AZD8055 against neuroblastoma cells in vitro and in vivo
Xu, D., Toyoda, H., Yuan, X., Qi, L., Chelakkot, V. S., Morimoto, M., Hanaki, R., Kihira, K., Hori, H., Komada, Y., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.02.032 · Cited by 31
Peinemann, F., van Dalen, E. C., Kahangire, D. A., & Berthold, F. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010685.pub2 · Cited by 33
Dome, J. S., Galindo, C. R., Spunt, S. L., & Santana, V. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00092-x · Cited by 32
Yang, X., Chen, J., Wang, N., Liu, Z., Li, F., Zhou, J., & Tao, B. (2018) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2018.08.046 · Cited by 28
Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities
Shawraba, F., Hammoud, H., Mrad, Y., Saker, Z., Fares, Y., Harati, H., Bahmad, H. F., & Nabha, S. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00898-1 · Cited by 30
McNerney, K. O., Karageorgos, S. A., Ferry, G. M., Wolpaw, A. J., Burudpakdee, C., Khurana, P., Toland, C., Vemu, R., Vu, A. T., Hogarty, M. D., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2075204 · Cited by 29
“Dinutuximab is purported to exert its antitumor effect via antibody-dependent cellular cytotoxicity (ADCC) as well as complement-dependent cytotoxicity.(9) In our evaluation of the TH-MYCN TME, we did not observe differences in intratumoral NK, T, and iNKT cell frequencies between 14G2a and isotype-control groups at t…”
ResultNew Approaches Towards Targeted Therapy for Childhood Neuroblastoma
Dalianis, T., Lukoseviciute, M., Holzhauser, S., & Kostopoulou, O. N. (2023) · Anticancer Research · doi:10.21873/anticanres.16570 · Cited by 33
Declining childhood and adolescent cancer mortality: Great progress but still much to be done
Pritchard‐Jones, K., & Hargrave, D. R. (2014) · Cancer · doi:10.1002/cncr.28745 · Cited by 31
“18.(14) However, as an example of a new cancer therapeutic approach, it is hoped that immunotherapy may be a promising development not only in neuroblastoma but also in other childhood malignancies, such as treatment with chimeric antigen receptormodified T cells in ALL.”
BackgroundKroesen, M., Brok, I. C., Reijnen, D., Hout-Kuijer, M. A. V., Zeelenberg, I. S., den Brok, M. H., Hoogerbrugge, P. M., & Adema, G. J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1663-y · Cited by 28
“In a recent phase III trial, immunotherapy was added to the current standard therapy regimen, which consists of chemotherapy, surgery, radiation therapy and autologous stem cell transplantation followed by retinoic acid treatment [2].”
BackgroundBone Sarcomas: From Biology to Targeted Therapies
Gaspar, N., Giannatale, A. D., Geoerger, B., Rédiní, F., Corradini, N., Entz‐Werlé, N., Tirode, F., Marec‐Bérard, P., Gentet, J., Laurence, V., et al. (2012) · Sarcoma · doi:10.1155/2012/301975 · Cited by 31
“This neuroectodermic marker is targeted by an anti-GD2 monoclonal antibody, which, combined with IL2 and GM-CSF, has significantly increased the survival of metastatic neuroblastoma [125].”
BackgroundAntibody-Based Immunotherapy of Solid Cancers: Progress and Possibilities
Nicodemus, C. F. (2015) · Immunotherapy · doi:10.2217/imt.15.57 · Cited by 28
Cordeau, M., Belounis, A., Lelaidier, M., Cordeiro, P., Sartelet, H., Herblot, S., & Duval, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164401 · Cited by 28
Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue
Gains, J. E., Sebire, N. J., Moroz, V., Wheatley, K., & Gaze, M. N. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3856-4 · Cited by 30
“Monoclonal antibodies directed against GD2 are an established treatment in the immunotherapy of neuroblastoma [4, 19], and radio-labelled versions have been explored as potential vectors for molecular radiotherapy [20].”
Luca, R. D., & Neri, D. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2194-0 · Cited by 28
Makin, G. (2018) · Paediatrics and Child Health · doi:10.1016/j.paed.2018.02.002 · Cited by 28
Cytokines in Neuroblastoma: From Pathogenesis to Treatment
Pistoia, V., Bianchi, G., Borgonovo, G., & Raffaghello, L. (2011) · Immunotherapy · doi:10.2217/imt.11.80 · Cited by 31
Tong, W., Maira, M., Gagnon, M., & Saragovi, H. U. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134255 · Cited by 29
“Activation of NMDA-R and Ca fluxes by anti-GD2 mAbs may explain the morphineintractable visceral pain reported in animal studies [9, 12, 13] and in human clinical trials using therapeutic anti-GD2 mAbs [4, 6, 8, 10, 11].”
BackgroundSiebert, N., Seidel, D., Eger, C., Jüttner, M., & Lode, H. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107692 · Cited by 27
Immunotherapy in Pediatric Solid Tumors—A Systematic Review
Marayati, R., Quinn, C. H., & Beierle, E. A. (2019) · Cancers · doi:10.3390/cancers11122022 · Cited by 29
“18 (dinutuximab) resulted in higher rates of event-free (66% versus 46%) and overall (86% versus 75%) survival after 2 years compared to standard therapy alone in children with high-risk neuroblastoma [18].”
MethodResultKoumarianou, A. A., & Durán, J. (2021) · Cancers · doi:10.3390/cancers13030363 · Cited by 35
“The efficacy of MAbs targeting GD2 in neuroblastoma has led to the approval of dinutuximab as consolidation treatment for patients with neuroblastoma [58] and incited the research of newer, bispecific antibodies.”
BackgroundA novel multimeric IL15/IL15Rα-Fc complex to enhance cancer immunotherapy
Xu, H., Buhtoiarov, I. N., Guo, H.-F., & Cheung, N. V. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1893500 · Cited by 27
“In a phase III randomized clinical trial led by the Children’s Oncology Group, dinutuximab in combination with interleukin-2 (IL2) and GM-CSF produced a statistically significant improvement in overall survival (OS).(38,39) Chimeric antigen receptor-modified ONCOIMMUNOLOGY e1893500-11”
BackgroundWieczorek, A., Manzitti, C., Garaventa, A., Gray, J. C., Papadakis, V., Valteau‐Couanet, D., Zachwieja, K., Pöetschger, U., Pribill, I., Fiedler, S., et al. (2022) · Cancers · doi:10.3390/cancers14081919 · Cited by 27
“Given that anti-GD2 antibody therapy for high-risk neuroblastoma has been developed in combination with cytokines, in particular IL-2 [1,3], it is important to note that uncommon, but severe, neurotoxicity has also been reported for IL-2 therapy”
BackgroundInfluentialWebb, E. R., Moreno-Vicente, J., Easton, A., Lanati, S., Taylor, M., James, S., Williams, E. L., English, V., Penfold, C., Beers, S. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104995 · Cited by 31
GM‐CSF , G‐CSF or no cytokine therapy with anti‐GD2 immunotherapy for high‐risk neuroblastoma
Mora, J., Modak, S. I., Kinsey, J., Ragsdale, C. E., & Lazarus, H. M. (2023) · International Journal of Cancer · doi:10.1002/ijc.34815 · Cited by 27
“Five-year EFS was 57% for patients who received post-consolidation/maintenance therapy with dinutuximab plus sargramostim, IL-2 and isotretinoin in the long-term follow-up of the registration trial, 19,65 compared to 46% for patients randomized to isotretinoin only ( P = .042).”
BackgroundEmerging drugs for neuroblastoma
Castel, V., Segura, V., & Berlanga, P. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.796927 · Cited by 33
“Multimodality therapy including myeloablative therapy with autologous stem-cell transplantation (SCT), differentiation therapy using 13-cis-retinoic acid and immunotherapy using anti-GD2 antibody can improve response, and has shown efficacy in randomized trials [22-24], but the maintenance of long-term tumor control r…”
BackgroundWei, J. S., Johansson, P. A., Chen, L., Song, Y., Tolman, C., Li, S., Hurd, L., Patidar, R., Wen, X., Badgett, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077731 · Cited by 28
“Despite aggressive multimodal therapy, the current survival rate for high-risk neuroblastoma patients remains <40% [2].”
BackgroundMise, N., Takami, M., Suzuki, A., Kamata, T., Harada, K., Hishiki, T., Saito, T., Terui, K., Mitsunaga, T., Nakata, M., et al. (2016) · Cancer Science · doi:10.1111/cas.12882 · Cited by 27
Ribeiro, D., Klarqvist, M. D. R., Westermark, U., Oliynyk, G., Dzieran, J., Kock, A., Banares, C. S., Hertwig, F., Johnsen, J. I., Fischer, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.052 · Cited by 29
Ferris, M. J., Danish, H. H., Switchenko, J. M., Deng, C., George, B. A., Goldsmith, K. C., Wasilewski, K., Cash, W. T., Khan, M. K., Eaton, B. R., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.11.043 · Cited by 27
“After the conclusion of RT, patients typically received maintenance cis-retinoic acid for at least 6 cycles, or 6 cycles of immunotherapy with the monoclonal anti-GD2 antibody Unituxin/interleukin-2/granulocyte-macrophage colony-stimulating factor in addition to cis-retinoic acid (19).”
Nguyen, R., Sahr, N. A., Sykes, A. D., McCarville, M. B., Federico, S. M., Sooter, A., Cullins, D. L., Rooney, B., Janssen, W. E., Talleur, A. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000176 · Cited by 30
Ding, Y., Panzer, J. A., Maris, J. M., Castañeda, A., Gómez‐Chiari, M., & Mora, J. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26732 · Cited by 27
Self-citationA proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma
Weiner, A. K., Radaoui, A. B., Tsang, M., Martínez, D., Conkrite, K. L., Patel, K., Sidoli, S., Delaidelli, A., Modi, A., Rokita, J. L., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.003 · Cited by 28
Self-citationThe optimal timing of surgical resection in high-risk neuroblastoma
Rojas, Y., Jaramillo, S., Lyons, K. A., Mahmood, N., Wu, M.-F., Liu, H., Vasudevan, S. A., Guillerman, R. P., Louis, C. U., Russell, H. V., et al. (2016) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2016.05.021 · Cited by 26
Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling
Lombardo, S. D., Presti, M., Mangano, K., Petralia, M. C., Basile, M. S., Libra, M., Candido, S., Fagone, P., Mazzon, E., Nicoletti, F., et al. (2019) · Brain Sciences · doi:10.3390/brainsci9090221 · Cited by 26
“The standard of care (SOC) for NBM consists of surgery, dose-intensive chemotherapy, radiation, and immunotherapeutic targeting of the disialoganglioside, GD2 [4,5].”
BackgroundAiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy
Bartish, M., Rincon, S. V. D., Rudd, C. E., & Saragovi, H. U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.564499 · Cited by 28
Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma
Dalton, K. M., Krytska, K., Lochmann, T. L., Sano, R., Casey, C. E., D'Aulerio, A., Khan, Q. A., Crowther, G. S., Coon, C. M., Cai, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0710 · Cited by 30
“The SK-N-AS, SK-N-BE (2), SK-N-SH, SK-N-DZ, IMR-5, HCE-T, and SK-N-FI cell lines were cultured in DMEM/F12 (50:50) supplemented with 10% FBS.”
BackgroundMethodInfluentialNSUN2 gene rs13181449 C>T polymorphism reduces neuroblastoma risk
Lin, L., Deng, C., Zhou, C., Zhang, X., Zhu, J., Liu, J., Wu, H., & He, J. (2022) · Gene · doi:10.1016/j.gene.2022.147120 · Cited by 31
Mora, J., Castañeda, A., Gorostegui, M., Varo, A., Pérez‐Jaume, S., Simão, M., Pérez, J. P. M., Garraus, M., Larrosa, C., Salvador, N., et al. (2023) · Cancers · doi:10.3390/cancers15092535 · Cited by 26
“Clinical trials using anti-GD2 immunotherapy demonstrated a significant improvement in EFS and OS [24,25].”
BackgroundLi, X., Li, W., Xu, L., & Song, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002818 · Cited by 27
Neuroblastoma in the Era of Precision Medicine: A Clinical Review
Wahba, A., Wolters, R., & Foster, J. H. (2023) · Cancers · doi:10.3390/cancers15194722 · Cited by 26
“All subsequent patients were treated with dinutuximab, GMCSF, and IL-2, with a 5-year EFS of 73.2% vs. 56.6% ( p = 0.045) [30,31].”
MethodInfluentialBioactive sphingolipids as emerging targets for signal transduction in cancer development
Jia, W., Yuan, J., Zhang, J., Li, S., Lin, W., & Cheng, B. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189176 · Cited by 27
Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells
Cartledge, D. M., Colella, R., Glazewski, L., Lu, G., & Mason, R. W. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9826-6 · Cited by 26
Vittorio, O., Grand, M. L., Makharza, S. A., Curcio, M., Tucci, P., Iemma, F., Nicoletta, F. P., Hampel, S., & Cirillo, G. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.11.005 · Cited by 26
Segatori, V. I., Cuello, H., Gulino, C. A., Albertó, M., Venier, C., Guthmann, M. D., Demarco, I. A., Alonso, D. F., & Gabri, M. R. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2188-y · Cited by 26
“With the approval of dinutuximab, a chimeric antiGD2 therapeutic Ab, the ganglioside GD2 became the first glycosphingolipid proven as an effective target antigen for passive immunotherapy against neuroblastoma [54].”
Backgroundvan den Bijgaart, R. J. E., Kroesen, M., Brok, I. C., Reijnen, D., Wassink, M., Boon, L., Hoogerbrugge, P. M., & Adema, G. J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1817653 · Cited by 27
“Nevertheless, a major side effect is pain, thought to be a consequence of complement activation, which remains a clinical burden.(9,31) There are efforts to optimize the efficacy of anti-GD2 mAb-based (combination) therapies while reducing its side effects, for example, by using CAR T cells or carbohydrate-based vacci…”
BackgroundResultAnti-Gb3 Monoclonal Antibody Inhibits Angiogenesis and Tumor Development
Desselle, A., Chaumette, T., Gaugler, M., Cochonneau, D., Fleurence, J., Dubois, N., Hulin, P., Aubry, J., Birklé, S., & Paris, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045423 · Cited by 29
“They consist of a hydrophobic ceramide membrane anchor and a hydrophilic cell surface-exposed oligosaccharide chain, accessible to cell surface recognition molecules, making them candidate targets for oncological applications [3].”
BackgroundDuke, E. S., Bradford, D., Sinha, A. K., Mishra-Kalyani, P. S., Lerro, C. C., Rivera, D. R. R., Wearne, E., Miller, C. P., Leighton, J. C., Sabit, H., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00546 · Cited by 27
New power in cancer immunotherapy: the rise of chimeric antigen receptor macrophage (CAR-M)
Jing, J., Chen, Y., Chi, E., Li, S., He, Y., Wang, B., Shen, H., Fan, L., Wang, J., Shangguan, T., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07115-9 · Cited by 27
“Although FDA-approved anti-GD2 monoclonal antibodies like dinutuximab and naxitamab show clinical efficacy, their administration is often accompanied by severe pain requiring opioid analgesia [82–84].”
Carlson, L.-M., & Kogner, P. (2013) · OncoImmunology · doi:10.4161/onci.24658 · Cited by 26
State of the Art in Immunotherapy of Neuroblastoma
Jabbari, P., Hanaei, S., & Rezaei, N. (2019) · Immunotherapy · doi:10.2217/imt-2019-0018 · Cited by 25
In Silico Insights on GD2 : A Potential Target for Pediatric Neuroblastoma
Limaye, A., Sweta, J., Madhavi, M., Mudgal, U., Mukherjee, S., Sharma, S., Hussain, T., Nayarisseri, A., & Singh, S. K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191112115333 · Cited by 25
Wu, D., Liu, X., Mu, J., Yang, J., Wu, F., & Zhou, H. (2022) · Biomolecules · doi:10.3390/biom12030392 · Cited by 29
Advances in the Immunomodulatory Properties of Glycoantigens in Cancer
da Costa, V., & Freire, T. (2022) · Cancers · doi:10.3390/cancers14081854 · Cited by 27
E, E. R. P., Chugh, R. K., Ryan, C. W., Agulnik, M., Milhem, M. M., George, S., Jones, R. L., Chmielowski, B., Tine, B. A. V., Tawbi, H. A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.09.003 · Cited by 26
Li, Q., Wang, J., Yang, C., Hu, A., Li, D., Wang, X., Guo, Y., Zhou, Y., Chen, G., Bao, B., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030754 · Cited by 25
“Although the 2-year overall survival of patients receiving the adjuvant anti-GD2 monoclonal antibody with interleukin-2 (IL-2), granulocyte-macrophage colonystimulating factor (GM-CSF), and retinoic acid rose to 86%, approximately 50% of the patients would relapse and eventually die from their disease [35], and the ac…”
BackgroundLee, J. Y., Jonus, H. C., Sadanand, A., Branella, G. M., Maximov, V. D., Suttapitugsakul, S., Schniederjan, M., Shim, J., Ho, A. K. S., Parwani, K. K., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101091 · Cited by 33
“Our design used a CD28based co-stimulatory domain, which has not shown to be as successful in NB or other solid tumors preclinically compared with 4-1BB or dual 4-1BB/CD28 signaling.41–45 Future investigations should compare CD28 vs. 4-1BB signaling domains as an optimization strategy for PTK7-targeting CARs for NB.”
BackgroundInfluentialGlobal Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
Larrosa, C., Mora, J., & Cheung, N. V. (2023) · Cancers · doi:10.3390/cancers15143729 · Cited by 25
“Coadministration of 3F8 mAb with recombinant human GM-CSF strongly enhanced ADCC and was implemented into the standard of care [50,53,132,133] (Table 1).”
BackgroundMethodInfluentialPrinciples and current clinical landscape of NK cell engaging bispecific antibody against cancer
Tian, H., Guan, B., Li, H., Tu, X., Zhang, C., & Tang, B. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2256904 · Cited by 25
Ex Vivo Activation of CD56+ Immune Cells That Eradicate Neuroblastoma
Rujkijyanont, P., Chan, W. K., Eldridge, P. W., Lockey, T. D., Holladay, M. S., Rooney, B., Davidoff, A. M., Leung, W. H., & Vong, Q. P. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3322 · Cited by 27
“Over the past decade, the addition of isotretinoin and immunotherapy with anti-GD2 mAbs in combination with IL-2 and GM-CSF has emerged as promising therapy in high-risk neuroblastoma (8, 11).”
Langenau, D. M., Sweet-Cordero, A., Wechsler‐Reya, R. J., & Dyer, M. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1308 · Cited by 28
“This point is particularly important because the immune system plays a crucial, wellestablished role in tumor response, and immunomodulatory therapies such as a-GD2 antibody for neuroblastoma (57) or a-CTLA-4/a-PD-L1 for osteosarcoma (48) cannot be tested in immunocompromised PDX models.”
Boyineni, J., Tanpure, S., Gnanamony, M., Antony, R., Fernández, K. S., Lin, J., Pinson, D. M., & Gondi, C. S. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3646 · Cited by 25
Treatment of Neuroblastoma with an Engineered “Obligate” Anaerobic Salmonella typhimurium Strain YB1
Ning, B., Yu, B., Chan, S., Chan, J.-L., Huang, J., & Chan, G. (2017) · Journal of Cancer · doi:10.7150/jca.18776 · Cited by 25
Advances in the Surgical Treatment of Neuroblastoma
Luo, Y., Cui, X., Yang, L., Zhang, D., & Wang, J. (2018) · Chinese Medical Journal · doi:10.4103/0366-6999.241803 · Cited by 25
“We Chinese Medical Journal ¦ October 5, 2018 ¦ Volume 131 ¦ Issue 19 2335 conclude that ≥90% resection is both feasible and safe in most patients with high‑risk NB.[28] Hence, the treatment strategy may have advantages in terms of surgical invasiveness and the rates of postoperative complications and recurrence.”
BackgroundInfluentialCox, E. C., Thornlow, D. N., Jones, M. A., Fuller, J. L., Merritt, J. H., Paszek, M. J., Alabi, C. A., & DeLisa, M. P. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3119 · Cited by 25
“One notable example along these lines is the synthetic immunotherapy dinutuximab, a first-in-class monoclonal antibody (mAb) that recognizes the disialoganglioside GD2 found on the surface of neuroblastic tumor cells and is administered as part of a multi-agent, multimodality therapy to pediatric patients with high-ri…”
BackgroundChallenges and Opportunities for Childhood Cancer Drug Development
Houghton, P. J., & Kurmasheva, R. T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016972 · Cited by 27
Emerging therapeutic targets for neuroblastoma
Aravindan, N., Herman, T. S., & Aravindan, S. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1790528 · Cited by 26
Fasanya, H. O., Dopico, P., Yeager, Z., Fan, Z. H., & Siemann, D. W. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100357 · Cited by 26
“The differentiation of tumor associated glycolipids from normal tissue, in principle enables the selective detection and therapeutic targeting of cancer cells [18,37].”
BackgroundNeuroblastoma: A 20‐year experience in a UK regional centre
Salim, A., Mullassery, D., Pizer, B. L., McDowell, H. P., & Losty, P. D. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23149 · Cited by 25
mTOR Inhibitors and Autosomal Dominant Polycystic Kidney Disease
Grantham, J. J., Bennett, W. M., & Perrone, R. D. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1010845 · Cited by 25
Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma
Strijker, J. G. M., Pascual‐Pasto, G., Grothusen, G. P., Kalmeijer, Y. J., Kalaitsidou, E., Zhao, C., McIntyre, B. C., Matlaga, S., Visser, L. L., Barisa, M., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115263 · Cited by 26
Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine
Modak, S. I., & Sun, . (2012) · OncoTargets and Therapy · doi:10.2147/ott.s14578 · Cited by 26
“25 Activation of PI3K generates phosphatidylinositol-3,4,5-trisphosphate (PIP3) which then anchors the serine/threonine kinase Akt to the plasma membrane via the binding of PIP3 to the pleckstrin homology (PH) domain of Akt.”
Targeting RAS in neuroblastoma: Is it possible?
Lin, L., Miao, L., Lin, H., Cheng, J., Li, M., Zhuo, Z., & He, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108054 · Cited by 24
Genotype analysis of tumor‐initiating cells expressing CD133 in neuroblastoma
Cournoyer, S., Nyalendo, C., Addioui, A., Belounis, A., Beaunoyer, M., Aumont, A., Teira, P., Duval, M., Fernandes, K. J. L., Fetni, R., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21964 · Cited by 24
Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma
Kandula, S., Prabhu, R. S., Nanda, R. H., Switchenko, J. M., Cash, T., Qayed, M. D., Katzenstein, H. M., & Esiashvili, N. (2014) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000264 · Cited by 24
Mass spectrometry of gangliosides in extracranial tumors: Application to adrenal neuroblastoma
Robu, A., Vukelić, Ž., Schiopu, C., Căpitan, F., & Zamfir, A. D. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.06.005 · Cited by 25
Lopez-Barcons, L. A., Maurer, B. J., Kang, M. H., & Reynolds, C. P. (2017) · International Journal of Cancer · doi:10.1002/ijc.30706 · Cited by 27
Self-citationOptimization of liposomal topotecan for use in treating neuroblastoma
Chernov, L., Deyell, R. J., Anantha, M., Santos, N. D., Gilabert‐Oriol, R., & Bally, M. B. (2017) · Cancer Medicine · doi:10.1002/cam4.1083 · Cited by 24
Verly, I. R. N., Kuilenburg, A. B. P., Abeling, N. G. G. M., Goorden, S. M. I., Fiocco, M. F., Vaz, F. M., van Noesel, M. M., Zwaan, C. M., Kaspers, G. J. L., Merks, J. H. M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.025 · Cited by 24
ROR1 and ROR2—novel targets for neuroblastoma
Dave, H., Butcher, D. O., Anver, M. R., & Bollard, C. M. (2019) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2019.1646365 · Cited by 27
“combined with granulocyte monocyte colony stimulating factor (GM-CSF) or interleukin-2 was added to standard isotretinoin therapy.(3) Despite these advances, only 50% of”
MethodThe Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers
Kimpo, M. S., Oh, B. L. Z., & Lee, S. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0837-8 · Cited by 26
MIBG Therapy for Neuroblastoma: Precision Achieved With Dosimetry, and Concern for False Responders
Rubio, P., Galán‐Gómez, V., Rodado, S., Plaza, D., & Martínez, L. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00173 · Cited by 24
“, which showed a 20% survival advantage for patients receiving anti-disialoganglioside (GD2) antibody therapy (3, 4).”
BackgroundSedky, N. K., Hamdan, A. A., Emad, S., Allam, A. L., Ali, M. K., & Tolba, M. F. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02779-x · Cited by 24
“This novel approach has met great success in different types of tumors, including melanoma [16], breast cancer [17], neuroblastoma [18], non-small cell lung cancer [19] and colorectal cancer [20].”
BackgroundGutova, M., Goldstein, L., Metz, M. Z., Hovsepyan, A., Tsurkan, L. G., Tirughana, R., Tsaturyan, L., Annala, A. J., Synold, T. W., Wan, Z., et al. (2016) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.11.004 · Cited by 25
Self-citationThe Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer
Poot, A. J., Lam, M. G. E. H., & van Noesel, M. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578286 · Cited by 23
O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells
Cheng, J., Hung, J., Lin, J., Lo, F., Huang, J., Chiou, S.-P., Wang, Y., Lin, R., Wu, J., Yu, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791551 · Cited by 24
“Dinutuximab was approved for the treatment of high-risk neuroblastoma in the setting of minimal residual disease (42) and recently in neuroblastoma patients with refractory/resistant disease (43).”
BackgroundSelf-citationMatteo, S. D., Avanzini, M. A., Pelizzo, G., Calcaterra, V., Croce, S., Spaggiari, G. M., Theuer, C. P., Zuccotti, G., Moretta, L., Pelosi, A., et al. (2022) · Cancers · doi:10.3390/cancers15010019 · Cited by 23
“Despite chemotherapy and immunotherapy approaches, approximately 40% of patients with NB still relapse [2,3].”
Background
Metadata
- Authors
- Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., Shimada, H., Grupp, S. A., Seeger, R., Reynolds, C. P., Buxton, A., Reisfeld, R. A., Gillies, S. D., Cohn, S. L., Maris, J. M., & Sondel, P. M.
- Affiliations
- University of California San Diego (US)
- Levine Children's Hospital (US)
- Boston Children's Hospital (US)
- Duke Medical Center (US)
- National Institutes of Health (US)
- University of Southern California (US)
- University of California, San Francisco (US)
- Children's Hospital of Philadelphia (US)
- Texas Tech University (US)
- Children's Oncology Group (US)
- Scripps Research Institute (US)
- University of Chicago (US)
- University of Wisconsin–Madison (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-09-30
- Volume
- 363
- Issue
- 14
- Pages
- 1324-1334
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3086629
- OpenAlex
- W2130465135
- Cited by
- 1,835
- References
- 38
- Citations by year
- 2026: 99 · 2025: 98 · 2024: 124 · 2023: 133 · 2022: 142 · 2021: 151 · 2020: 156 · 2019: 107 · 2018: 107 · 2017: 139 · 2016: 105 · 2015: 115 · 2014: 95 · 2013: 103 · 2012: 92
- FWCI
- 49.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CA98543)
- U.S. Food and Drug Administration (FD-R-002319)
- National Cancer Institute (CA‐98413, U10 CA-98413, U10-CA98543, U10CA098413, R01CA032685, U10CA29139, U10CA029139, U10CA098543, CA-98543)
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- neuroblastoma, GD2, GM-CSF, interleukin-2, isotretinoin, immunotherapy, high-risk neuroblastoma, event-free survival, overall survival, disialoganglioside, stem cell transplantation, multimodal therapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Child, Child, Preschool, Combined Modality Therapy, Drug Therapy, Combination, Gangliosides, Humans, Immunotherapy, Infant, Interleukin-2, Neuroblastoma, Isotretinoin, Survival Analysis, Granulocyte-Macrophage Colony-Stimulating Factor, Stem Cell Transplantation, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.